Cellectis - חוב לטווח קצר של החברה CLLS

Cellectis S.A. (CLLS) specializes in developing innovative gene-cell therapies to combat oncology. The company's management, composed of industry pioneers, is betting on the strategic development of CAR-T technologies and collaboration with pharmaceutical behemoths. Business stability relies on licensing payments and test safety, with the current metric standing at 0.01. This price chart on GURU.Markets confirms the influence of these fundamental factors on the asset's value.

Fundamental asset screening begins with an analysis of liquidity and debt load. This indicator aggregates all liabilities with maturities of up to twelve months, reflecting current financial stability. The trend in total short-term debt allows for an assessment of cash gap risks or the efficiency of leveraged capital utilization. For Cellectis S.A. (CLLS), this balance is critical when financing strict compliance with environmental regulations in laboratories. Controlling zone purity and bio-waste disposal require a stable operating cash flow.